bismuth quadruple therapy
PreclinicalSmall molecule
bismuth quadruple therapy is one of 30 small molecule programs targeting Peptic Ulcer Disease. It is currently in Preclinical.
4
Indications
7
Total Trials
4
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Helicobacter Pylori Eradication
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Flagyl
DDePuy Orthopaedics
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Potassium Citrate
MMission Pharmacal
Approved
Levaquin
WWim Janssens
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Aciphex
Akero TherapeuticsApproved
Minocin
TTriax
Approved
Furoxone
UUniversity of New Hampshire
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bismuth Quadruple Therapy1 trial
Helicobacter Pylori Infection1 trial
Helicobacter Pylori Eradication1 trial
2 more indications
Peptic Ulcer Disease1 trial
Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease
Recruiting·—·N/A·NCT07260006·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for bismuth quadruple therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details